Seres Therapeutics (MCRB) Q4 2024 earnings summary

Executive summary

• SER-155 achieved a 77% relative risk reduction in bloodstream infections in allo-HSCT patients in Phase I-B, leading to FDA Breakthrough Therapy and Fast Track designations, with ongoing engagement to refine Phase II study design and manufacturing.

• SER-155 demonstrated favorable safety, reduced febrile neutropenia, and lower antibiotic use in clinical trials.

• Company is seeking development partners to maximize SER-155's potential and is exploring indication expansion to other vulnerable patient groups.

• Sale of VOWST business to Nestlé completed, providing $155 million upfront, $50 million in January 2025, and future milestone payments, making the company debt-free.

• Cash runway expected into Q1 2026, supported by current cash, received and expected Nestlé payments, and operating plans.

Financial highlights

• Net loss from continuing operations was $125.8 million for 2024, down from $190.1 million in 2023; Q4 2024 net loss was $15.7 million, down from $34.7 million in Q4 2023.

• Net income from discontinued operations was $125.9 million in 2024, up from $76.4 million in 2023, mainly due to a $146.7 million gain on the VOWST sale.

• R&D expenses for 2024 were $64.6 million, down from $117.6 million in 2023; G&A expenses were $53.2 million, down from $77.5 million.

• As of December 31, 2024, cash and cash equivalents were $30.8 million; $50 million installment received in January 2025, with $25 million more expected in July 2025.

• Operations expected to be funded into Q1 2026, with additional payments from the VOWST transaction anticipated.

Outlook and guidance

• Preparing for a Phase II or seamless Phase II/III study of SER-155, with interim results projected within 12 months of study initiation and top-line data nine months later.

• Draft study protocol to be submitted to FDA in Q2 2025, with input from potential partners.

• Anticipated milestone payments of up to $275 million from Nestlé based on VOWST net sales.

• Focus remains on SER-155, with continued IND-enabling work for SER-147 and exploration of research collaborations.